Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the existence of gene mutations based on images of leukemia cells.

Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that ...

The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a ...

Researchers from Karl Landsteiner University of Health Sciences (KL Krems) have discovered that combining two existing drugs ...

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma ...

In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...